Identification

Name
Sulfasalazine
Accession Number
DB00795  (APRD00152, DB08518)
Type
Small Molecule
Groups
Approved
Description

A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)

Structure
Thumb
Synonyms
  • 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid
  • 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid
  • 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene
  • 5-((P-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid
  • 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid
  • 5-(P-(2-Pyridylsulfamyl)phenylazo)salicylic acid
  • Azopyrin
  • Salazosulfapiridina
  • Salazosulfapyridine
  • Salazosulfapyridinum
  • Salicylazosulfapyridine
  • Sulfasalazin
  • Sulfasalazina
  • Sulfasalazine
  • Sulfasalazinum
External IDs
NSC-203730 / NSC-667219 / SSZ
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Sulfasalazine Tab 500mgTablet500 mgOralApotex Corporation1978-12-31Not applicableCanada
AzulfidineTablet500 mg/1OralPharmacia & Upjohn Inc1950-06-20Not applicableUs
Azulfidine EN-tabsTablet, delayed release500 mg/1OralPharmacia & Upjohn Inc1950-06-20Not applicableUs
S.A.S. Enteric 500mgTablet, delayed release500 mgOralIcn Pharmaceuticals1979-12-312005-04-26Canada
Salazopyrin En-tabs 500 mgTablet, delayed release500 mgOralPfizer1995-12-31Not applicableCanada
Salazopyrin Enema 3.0gm/100mlSuspension3 gRectalKabi Pharmacia Canada Inc.1994-12-311996-09-10Canada
Salazopyrin Enema 3gm/100mlEnema3 gRectalPfizer1996-12-312006-08-02Canada
Salazopyrin Tab 500mgTablet500 mgOralPfizer1995-12-31Not applicableCanada
Sas Enema 3gm/100mlEnema3 gRectalIcn Pharmaceuticals1984-12-312005-04-26Canada
Sas Tab 500mgTablet500 mgOralIcn Pharmaceuticals1973-12-312005-04-26Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Orb-sulfasalazine ECTablet, delayed release500 mgOralOrbus Pharma IncNot applicableNot applicableCanada
PMS-sulfasalazine 500mg/tab USPTablet500 mgOralPharmascience Inc1984-12-31Not applicableCanada
PMS-sulfasalazine-E.C. Tab 500mgTablet, delayed release500 mgOralPharmascience Inc1984-12-31Not applicableCanada
Ratio-sulfasalazine EnTablet, delayed release500 mgOralRatiopharm Inc Division Of Teva Canada Limited1986-12-312008-08-01Canada
Ratio-sulfasalazine Tab 500mgTablet500 mgOralRatiopharm Inc Division Of Teva Canada Limited1986-12-312008-08-01Canada
SulfasalazineTablet500 mg/1OralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs00603 5801 28 nlmimage10 8f4547aa
SulfasalazineTablet500 mg/1OralGreenstone, Llc2003-07-01Not applicableUs
SulfasalazineTablet500 mg/1OralA S Medication Solutions2003-07-01Not applicableUs
SulfasalazineTablet500 mg/1OralRemedy Repack2017-01-30Not applicableUs
SulfasalazineTablet500 mg/1OralAv Pak2014-01-14Not applicableUs00591 0796 05 nlmimage10 580eac35
International/Other Brands
Asasurfan (Choseido Pharmaceutical) / Azulfdidina (Pfizer) / Azulfidine / Azulfin (Apsen) / Bomecon (Fu Seng) / Colo-Pleon (Sanofi-Aventis) / Disalazin (AC Farma) / Eminapyrin (Taiyo Pharmaceutical) / Flogostop (Ivax) / Iwata (Cadila) / Lanofen (Taisho Yakuhin) / Lazafin (Novell) / Pleon (Sanofi-Aventis) / Pyralin EN (Pfizer) / Reumazin (Aristopharma) / Saaz (Ipca) / Saaz-DS (Ipca) / Salasopyrine (Upjohn) / Salazar (Cadila) / Salazidin (Helcor) / Salazine (Opsonin) / Salazopirina (Jaba Recordati) / Salazoprin (Cazi) / Salazopyrin (Pfizer) / Salazopyrin EN (Pfizer) / Salazopyrin EN-Tabs (Pharmacia) / Sulcolon (Bernofarm) / Sulfacol (Drug International) / Weiliufen (Sunve) / Zopyrin (Han Lim)
Categories
UNII
3XC8GUZ6CB
CAS number
599-79-1
Weight
Average: 398.393
Monoisotopic: 398.068490268
Chemical Formula
C18H14N4O5S
InChI Key
NCEXYHBECQHGNR-QZQOTICOSA-N
InChI
InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+
IUPAC Name
2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid
SMILES
OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=NC=CC=C1

Pharmacology

Indication

For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.

Associated Conditions
Pharmacodynamics

Sulfasalazine is an anti-inflammatory indicated for the treatment of ulcerative colitis and rheumatoid arthritis.

Mechanism of action

The mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and in vitro models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of Sulfasalazine, SP and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown.

TargetActionsOrganism
AArachidonate 5-lipoxygenase
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
AProstaglandin G/H synthase 1
inhibitor
Human
APeroxisome proliferator-activated receptor gamma
agonist
Human
UInhibitor of nuclear factor kappa-B kinase subunit alpha
inhibitor
Human
UInhibitor of nuclear factor kappa-B kinase subunit beta
inhibitor
Human
UCystine/glutamate transporter
inhibitor
Human
UAcetyl-CoA acetyltransferase, mitochondrial
inhibitor
Human
UThromboxane-A synthase
antagonist
Human
UPhospholipase A2
antagonist
Human
Absorption
Not Available
Volume of distribution
  • 7.5 ± 1.6 L
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA with the feces.

Half life

5-10 hours

Clearance
  • 1 L/h [IV administration]
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Arylamine N-acetyltransferase 1NAT1*14ANot AvailableG > A | T > A | C > AADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 1NAT1*14BNot AvailableG > AADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 1NAT1*15Not AvailableC > TADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 1NAT1*17Not AvailableC > TADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 1NAT1*19ANot AvailableC > TADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 1NAT1*19BNot AvailableC > T | C > TADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 1NAT1*22Not AvailableA > TADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*5ANot AvailableT > C | C > TADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*5BNot AvailableT > C | C > T | A > GADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*5CNot AvailableT > C | A > GADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*5DNot AvailableT > CADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*5ENot AvailableT > C | G > AADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*5FNot AvailableT > C | C > T | C > T | A > GADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*5GNot AvailableT > C | C > T | C > T | A > GADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*5HNot AvailableT > C | C > T | A > G | S287 FrameshiftADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*5INot AvailableT > C | C > T | A > T | A > GADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*5JNot AvailableT > C | C > T | G > AADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*6ANot AvailableG > A | C > TADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*6BNot AvailableG > AADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*6CNot AvailableG > A | C > T | A > GADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*6DNot AvailableG > A | C > T | T > CADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*6ENot AvailableG > A | C > TADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*7ANot AvailableG > AADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*7BNot AvailableG > A | C > TADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*10Not AvailableG > AADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*12DNot AvailableG > A | A > GADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*14ANot AvailableG > AADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*14BNot AvailableG > A | C > TADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*14CNot AvailableG > A | T > C | C > T | A > GADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*14DNot AvailableG > A | C > T | G > AADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*14ENot AvailableG > A | A > GADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*14FNot AvailableG > A | T > C | A > GADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*14GNot AvailableG > A | C > T | A > GADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*17Not AvailableA > CADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Arylamine N-acetyltransferase 2NAT2*19Not AvailableC > TADR InferredIncreased risk of Sulfapyridine dose related adverse effects, including skin rash.Details
Glucose-6-phosphate 1-dehydrogenaseVilleurbanneNot Available1000_1002delACCADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTorunNot Available1006A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSunderlandNot Available105_107delCATADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIwatsukiNot Available1081G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSerresNot Available1082C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTondelaNot Available1084_1101delCTGAACGAGCGCAAGGCCADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLoma LindaNot Available1089C->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAachenNot Available1089C->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTenriNot Available1096A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontpellierNot Available1132G>AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCalvo MackennaNot Available1138A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRileyNot Available1139T->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOlomoucNot Available1141T->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTomahNot Available1153T->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLynwoodNot Available1154G->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMadridNot Available1155C->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIowa, Walter Reed, SpringfieldNot Available1156A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBeverly Hills, Genova, Iwate, Niigata, YamaguchiNot Available1160G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHartfordNot Available1162A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePrahaNot Available1166A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKrakowNot Available1175T>CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWisconsinNot Available1177C->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNashville, Anaheim, PorticiNot Available1178G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAlhambraNot Available1180G->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBariNot Available1187C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePuerto LimonNot Available1192G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCovao do LoboNot Available1205C>AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseClinicNot Available1215G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUtrechtNot Available1225C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSuwalkiNot Available1226C->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRiversideNot Available1228G->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseJapan, ShinagawaNot Available1229G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKawasakiNot Available1229G->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMunichNot Available1231A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGeorgiaNot Available1284C->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSumareNot Available1292T->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTelti/KobeNot Available1318C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiago de Cuba, MoriokaNot Available1339G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarimaNot Available1358T->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFiguera da FozNot Available1366G->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmiensNot Available1367A>TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkok NoiNot Available1376G->T, 1502T->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFukayaNot Available1462G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCampinasNot Available1463G->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBuenos AiresNot Available1465C>TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseArakawaNot Available1466C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBrightonNot Available1488_1490delGAAADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKozukataNot Available159G->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmsterdamNot Available180_182delTCTADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNo nameNot Available202G->A, 376A->G, 1264C>GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSwanseaNot Available224T->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUrayasuNot Available281_283delAGAADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVancouverNot Available317C->G544C->T592C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMt SinaiNot Available376A->G, 1159C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePlymouthNot Available488G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVolendamNot Available514C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShinshuNot Available527A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChikugoNot Available535A->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTsukuiNot Available561_563delCTCADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePedoplis-CkaroNot Available573C>GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSantiagoNot Available593G->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMinnesota, Marion, Gastonia, LeJeuneNot Available637G->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCincinnatiNot Available637G->T, 1037A->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHarilaouNot Available648T->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNorth DallasNot Available683_685delACAADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahikawaNot Available695G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseDurhamNot Available713A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseStonybrookNot Available724_729delGGCACTADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWayneNot Available769C->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAveiroNot Available806G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCleveland CorumNot Available820G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLilleNot Available821A>TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBangkokNot Available825G>CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSugaoNot Available826C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLa JollaNot Available832T->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWexhamNot Available833C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePiotrkowNot Available851T>CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseWest VirginiaNot Available910G->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOmiyaNot Available921G->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaraNot Available953_976delCCACCAAAGGGTACCTGGAC GACCADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseManhattanNot Available962G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRehevotNot Available964T->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHoniaraNot Available99A->G / 1360C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTokyo, FukushimaNot Available1246G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChathamNot Available1003G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFushanNot Available1004C->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePartenopeNot Available1052G->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIerapetraNot Available1057C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnadiaNot Available1193A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAbenoNot Available1220A->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSurabayaNot Available1291G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePawneeNot Available1316G->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseS. AntiocoNot Available1342A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCassanoNot Available1347G->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHermoupolisNot Available1347G->C / 1360C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUnion,Maewo, Chinese-2, KaloNot Available1360C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAndalusNot Available1361G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCosenzaNot Available1376G->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCanton, Taiwan- Hakka, Gifu-like, Agrigento-likeNot Available1376G->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFloresNot Available1387C->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKaiping, Anant, Dhon, Sapporo-like, WoseraNot Available1388G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamogawaNot Available169C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCostanzoNot Available179T>CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAmazoniaNot Available185C->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSongklanagarindNot Available196T->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHechiNot Available202G->A / 871G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNamouruNot Available208T->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBao LocNot Available352T>CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCrispimNot Available375G->T, 379G->T383T->C384C>TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAcrokorinthosNot Available376A->G / 463C->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSanta MariaNot Available376A->G / 542A->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAnanindeuaNot Available376A->G / 871G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseVanua LavaNot Available383T->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseValladolidNot Available406C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBelemNot Available409C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLiuzhouNot Available442G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseShenzenNot Available473G>AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseTaipei “Chinese- 3”Not Available493A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseToledoNot Available496C>TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNaoneNot Available497G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNankangNot Available517T->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMiaoliNot Available519C->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMediterranean, Dallas, Panama‚ Sassari, Cagliari, BirminghamNot Available563C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseCoimbra ShundeNot Available592C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNilgiriNot Available593G>AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRadlowoNot Available679C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRoubaixNot Available811G>CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHaikouNot Available835A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-1Not Available835A->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMizushimaNot Available848A>GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOsakaNot Available853C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseViangchan, JammuNot Available871G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeoulNot Available916G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLudhianaNot Available929G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseFarroupilhaNot Available977C->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseChinese-5Not Available1024C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseRignanoNot Available130G>AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseOrissaNot Available131C->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseG6PDNiceNot Available1380G>CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKamiube, KeelungNot Available1387C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNeapolisNot Available1400C->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAuresNot Available143T->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSplitNot Available1442C->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKambosNot Available148C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenasePalestrinaNot Available170G>AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMetapontoNot Available172G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMusashinoNot Available185C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseAsahiNot Available202G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (202), Ferrara INot Available202G->A / 376A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMurcia OristanoNot Available209A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseUbe KonanNot Available241C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagosantoNot Available242G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGuangzhouNot Available274C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseHammersmithNot Available323T->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSinnaiNot Available34G->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (680)Not Available376A->G / 680G->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseA- (968), Betica,Selma, GuantanamoNot Available376A->G / 968T->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSalerno PyrgosNot Available383T>GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseQuing YanNot Available392G->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseLagesNot Available40G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseIleshaNot Available466G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMahidolNot Available487G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMalagaNot Available542A->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSibariNot Available634A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMexico CityNot Available680G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseNanningNot Available703C->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseSeattle, Lodi, Modena, Ferrara II, Athens-likeNot Available844G->CADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseBajo MaumereNot Available844G->TADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseMontalbanoNot Available854G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseKalyan-Kerala, Jamnaga, RohiniNot Available949G->AADR InferredIncreased risk of dose-related hemolytic anemia.Details
Glucose-6-phosphate 1-dehydrogenaseGaoheNot Available95A->GADR InferredIncreased risk of dose-related hemolytic anemia.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinSulfasalazine may increase the anticoagulant activities of (R)-warfarin.Experimental
(S)-WarfarinSulfasalazine may increase the anticoagulant activities of (S)-Warfarin.Experimental, Investigational
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Sulfasalazine.Experimental
2,4-thiazolidinedioneSulfasalazine may increase the hypoglycemic activities of 2,4-thiazolidinedione.Investigational
4-hydroxycoumarinSulfasalazine may increase the anticoagulant activities of 4-hydroxycoumarin.Experimental
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when 9-(N-methyl-L-isoleucine)-cyclosporin A is combined with Sulfasalazine.Investigational
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Sulfasalazine.Approved
AbciximabThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Abciximab.Approved
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Sulfasalazine.Approved, Investigational
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Sulfasalazine.Investigational
AcarboseSulfasalazine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololSulfasalazine may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolSulfasalazine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetazolamideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideSulfasalazine may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Sulfasalazine.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Sulfasalazine.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Acetylsalicylic acid.Approved, Vet Approved
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Sulfasalazine.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Sulfasalazine.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Sulfasalazine.Approved
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Sulfasalazine.Investigational
AICA ribonucleotideSulfasalazine may increase the hypoglycemic activities of AICA ribonucleotide.Experimental, Investigational
AlaproclateAlaproclate may increase the antiplatelet activities of Sulfasalazine.Experimental
AlbiglutideSulfasalazine may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alclometasone.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sulfasalazine.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Aldosterone.Experimental, Investigational
AlectinibThe serum concentration of Sulfasalazine can be increased when it is combined with Alectinib.Approved, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Sulfasalazine.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Sulfasalazine.Approved, Investigational
Alendronic acidThe risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Alendronic acid.Approved
AliskirenThe risk or severity of renal failure and hypertension can be increased when Sulfasalazine is combined with Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alminoprofen.Experimental
AlogliptinSulfasalazine may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Sulfasalazine is combined with Aloxiprin.Experimental
AlprenololSulfasalazine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Sulfasalazine.Approved, Investigational
AlteplaseThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Alteplase.Approved
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Sulfasalazine.Approved
AlvocidibThe serum concentration of Alvocidib can be increased when it is combined with Sulfasalazine.Experimental, Investigational
AmbrisentanThe therapeutic efficacy of Ambrisentan can be decreased when used in combination with Sulfasalazine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Amcinonide.Approved
AmediplaseThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Amediplase.Investigational
AMG-222Sulfasalazine may increase the hypoglycemic activities of AMG-222.Investigational
AmikacinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Amiloride.Approved
Aminobenzoic acidThe therapeutic efficacy of Sulfasalazine can be decreased when used in combination with Aminobenzoic acid.Approved, Experimental
AminophenazoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Aminophenazone.Approved, Withdrawn
Aminosalicylic AcidThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Sulfasalazine is combined with Aminosalicylic Acid.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Sulfasalazine.Approved
Ammonium chlorideThe serum concentration of Sulfasalazine can be increased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
Amphotericin BThe risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Sulfasalazine.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Sulfasalazine.Approved, Investigational
AnagliptinSulfasalazine may increase the hypoglycemic activities of Anagliptin.Investigational
AnagrelideThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Anagrelide.Approved
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Sulfasalazine.Approved
AncrodThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Sulfasalazine.Investigational
AnisodamineSulfasalazine may decrease the antihypertensive activities of Anisodamine.Investigational
AnistreplaseThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Anistreplase.Approved
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Sulfasalazine.Approved
Anthrax vaccineThe risk or severity of infection can be increased when Anthrax vaccine is combined with Sulfasalazine.Approved
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Sulfasalazine.Approved
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Sulfasalazine.Approved, Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Antipyrine.Approved, Investigational
Antithrombin III humanThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Antithrombin III human.Approved
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Sulfasalazine.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Sulfasalazine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Apixaban.Approved
ApramycinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Apramycin.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Sulfasalazine.Approved, Investigational
ArbekacinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Arbekacin.Approved, Investigational
ArdeparinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Argatroban.Approved, Investigational
ArotinololSulfasalazine may decrease the antihypertensive activities of Arotinolol.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sulfasalazine.Approved, Investigational
AstaxanthinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Astaxanthin.Investigational
AtenololSulfasalazine may decrease the antihypertensive activities of Atenolol.Approved
AtorvastatinThe excretion of Atorvastatin can be decreased when combined with Sulfasalazine.Approved
AvatrombopagThe serum concentration of Sulfasalazine can be increased when it is combined with Avatrombopag.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Sulfasalazine.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Azapropazone.Withdrawn
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Sulfasalazine.Approved
Azilsartan medoxomilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Sulfasalazine.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Sulfasalazine.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Sulfasalazine.Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Sulfasalazine.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Sulfasalazine.Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Sulfasalazine.Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Sulfasalazine.Approved
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Sulfasalazine.Approved
BacitracinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Bacitracin.Approved, Vet Approved
BalaglitazoneSulfasalazine may increase the hypoglycemic activities of Balaglitazone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Balsalazide.Approved, Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Sulfasalazine.Approved, Investigational
BCG vaccineThe risk or severity of infection can be increased when BCG vaccine is combined with Sulfasalazine.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Sulfasalazine.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololSulfasalazine may decrease the antihypertensive activities of Befunolol.Experimental
BegelomabThe risk or severity of adverse effects can be increased when Begelomab is combined with Sulfasalazine.Experimental, Investigational
BekanamycinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Bekanamycin.Experimental
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Sulfasalazine.Approved, Investigational
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with Sulfasalazine.Approved
BelinostatThe risk or severity of adverse effects can be increased when Belinostat is combined with Sulfasalazine.Approved, Investigational
BemiparinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Bemiparin.Approved, Investigational
Bempedoic acidSulfasalazine may increase the hypoglycemic activities of Bempedoic acid.Investigational
BenazeprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Benazepril.Approved, Investigational
BenazeprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Benazeprilat.Experimental
BendamustineThe risk or severity of adverse effects can be increased when Bendamustine is combined with Sulfasalazine.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Sulfasalazine.Approved
BenfluorexSulfasalazine may increase the hypoglycemic activities of Benfluorex.Investigational, Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Benoxaprofen.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Sulfasalazine.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Benzydamine.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Sulfasalazine.Approved, Withdrawn
BeraprostThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Beraprost.Investigational
BesifloxacinSulfasalazine may increase the neuroexcitatory activities of Besifloxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Sulfasalazine.Approved, Vet Approved
BetaxololSulfasalazine may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Sulfasalazine.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Sulfasalazine.Approved, Investigational
BevacizumabThe risk or severity of adverse effects can be increased when Bevacizumab is combined with Sulfasalazine.Approved, Investigational
BevantololSulfasalazine may decrease the antihypertensive activities of Bevantolol.Approved
BexaroteneThe risk or severity of adverse effects can be increased when Bexarotene is combined with Sulfasalazine.Approved, Investigational
BietaserpineThe therapeutic efficacy of Bietaserpine can be decreased when used in combination with Sulfasalazine.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Sulfasalazine.Approved, Investigational
BisoprololSulfasalazine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Bivalirudin.Approved, Investigational
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Sulfasalazine.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Blinatumomab is combined with Sulfasalazine.Approved, Investigational
BopindololSulfasalazine may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Sulfasalazine.Approved, Investigational
BosentanThe therapeutic efficacy of Bosentan can be decreased when used in combination with Sulfasalazine.Approved, Investigational
BosutinibThe risk or severity of adverse effects can be increased when Bosutinib is combined with Sulfasalazine.Approved
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Botulinum Toxin Type B.Approved, Investigational
BQ-123The therapeutic efficacy of BQ-123 can be decreased when used in combination with Sulfasalazine.Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sulfasalazine.Approved, Investigational
BretyliumThe therapeutic efficacy of Bretylium can be decreased when used in combination with Sulfasalazine.Approved
BriakinumabThe risk or severity of adverse effects can be increased when Briakinumab is combined with Sulfasalazine.Investigational
BrigatinibThe serum concentration of Brigatinib can be increased when it is combined with Sulfasalazine.Approved, Investigational
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Sulfasalazine.Approved
BrinaseThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Brinzolamide.Approved
BrodalumabThe risk or severity of adverse effects can be increased when Brodalumab is combined with Sulfasalazine.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Sulfasalazine.Approved
BromocriptineSulfasalazine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucindololSulfasalazine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Sulfasalazine.Approved
BufexamacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bufexamac.Approved, Experimental
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Sulfasalazine.Experimental
BuforminSulfasalazine may increase the hypoglycemic activities of Buformin.Investigational, Withdrawn
BufuralolSulfasalazine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Sulfasalazine.Approved
BupranololSulfasalazine may decrease the antihypertensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Sulfasalazine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Sulfasalazine.Approved, Investigational
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Sulfasalazine.Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sulfasalazine.Approved
CadralazineThe therapeutic efficacy of Cadralazine can be decreased when used in combination with Sulfasalazine.Experimental
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Sulfasalazine.Experimental
CanagliflozinSulfasalazine may increase the hypoglycemic activities of Canagliflozin.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Sulfasalazine.Approved, Investigational
CandesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Sulfasalazine.Experimental
Candesartan cilexetilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan cilexetil is combined with Sulfasalazine.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Sulfasalazine.Experimental
CangrelorThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Cangrelor.Approved
CannabidiolThe serum concentration of Sulfasalazine can be increased when it is combined with Cannabidiol.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Sulfasalazine.Approved, Investigational
CapreomycinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Capreomycin.Approved
CaptoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Sulfasalazine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Carbaspirin calcium.Experimental, Investigational
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Sulfasalazine.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Sulfasalazine.Approved
CarbutamideSulfasalazine may increase the hypoglycemic activities of Carbutamide.Experimental
CarfilzomibThe risk or severity of adverse effects can be increased when Carfilzomib is combined with Sulfasalazine.Approved, Investigational
CarmegliptinSulfasalazine may increase the hypoglycemic activities of Carmegliptin.Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Sulfasalazine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololSulfasalazine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolSulfasalazine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Sulfasalazine.Experimental
CefacetrileThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefacetrile.Approved
CefaclorThe risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Sulfasalazine.Approved
CefadroxilThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefadroxil.Approved, Vet Approved, Withdrawn
CefalotinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefalotin.Approved, Investigational, Vet Approved
CefamandoleThe risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Sulfasalazine.Approved, Investigational
CefapirinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefapirin.Approved, Vet Approved
CefatrizineThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefatrizine.Experimental
CefazedoneThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefazedone.Experimental
CefazolinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefazolin.Approved
CefbuperazoneThe risk or severity of nephrotoxicity can be increased when Cefbuperazone is combined with Sulfasalazine.Experimental
CefcapeneThe risk or severity of nephrotoxicity can be increased when Cefcapene is combined with Sulfasalazine.Experimental
CefditorenThe risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Sulfasalazine.Approved, Investigational
CefepimeThe risk or severity of nephrotoxicity can be increased when Cefepime is combined with Sulfasalazine.Approved, Investigational
CefetametThe risk or severity of nephrotoxicity can be increased when Cefetamet is combined with Sulfasalazine.Experimental
CefmenoximeThe risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Sulfasalazine.Approved
CefmetazoleThe risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Sulfasalazine.Approved, Investigational
CefminoxThe risk or severity of nephrotoxicity can be increased when Cefminox is combined with Sulfasalazine.Approved
CefodizimeThe risk or severity of nephrotoxicity can be increased when Cefodizime is combined with Sulfasalazine.Experimental
CefonicidThe risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Sulfasalazine.Approved, Investigational
CefoperazoneThe risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Sulfasalazine.Approved, Investigational
CeforanideThe risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Sulfasalazine.Approved
CefotaximeThe risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Sulfasalazine.Approved
CefotetanThe risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Sulfasalazine.Approved
CefotiamThe risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Sulfasalazine.Approved, Investigational
CefoxitinThe risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Sulfasalazine.Approved
CefozopranThe risk or severity of nephrotoxicity can be increased when Cefozopran is combined with Sulfasalazine.Experimental
CefpiramideThe risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Sulfasalazine.Approved
CefpiromeThe risk or severity of nephrotoxicity can be increased when Cefpirome is combined with Sulfasalazine.Approved
CefpodoximeThe risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Sulfasalazine.Approved, Vet Approved
CefprozilThe risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Sulfasalazine.Approved
CefradineThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefradine.Approved
CefroxadineThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cefroxadine.Withdrawn
CefsulodinThe risk or severity of nephrotoxicity can be increased when Cefsulodin is combined with Sulfasalazine.Experimental
Ceftaroline fosamilThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Ceftaroline fosamil.Approved, Investigational
CeftazidimeThe risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Sulfasalazine.Approved
CeftezoleThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Ceftezole.Experimental
CeftibutenThe risk or severity of nephrotoxicity can be increased when Ceftibuten is combined with Sulfasalazine.Approved, Investigational
CeftizoximeThe risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Sulfasalazine.Approved, Investigational
CeftobiproleThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Ceftobiprole.Approved, Investigational
CeftriaxoneThe risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Sulfasalazine.Approved
CefuroximeThe risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Sulfasalazine.Approved
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Sulfasalazine.Approved, Investigational
CeliprololSulfasalazine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cephalexin.Approved, Investigational, Vet Approved
CephaloglycinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cephaloglycin.Approved
CephaloridineThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cephaloridine.Approved, Withdrawn
Cephalothin GroupThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Cephalothin Group.Experimental
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Sulfasalazine.Approved, Withdrawn
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Sulfasalazine.Approved
CertoparinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Certoparin.Approved, Investigational
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Sulfasalazine.Approved
ChloramphenicolThe risk or severity of adverse effects can be increased when Chloramphenicol is combined with Sulfasalazine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulfasalazine.Approved, Vet Approved
ChlorpropamideSulfasalazine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Sulfasalazine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ciclesonide.Approved, Investigational
CicletanineThe therapeutic efficacy of Cicletanine can be decreased when used in combination with Sulfasalazine.Investigational
CiglitazoneSulfasalazine may increase the hypoglycemic activities of Ciglitazone.Experimental
CilazaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Sulfasalazine.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cimicoxib.Investigational
CinoxacinSulfasalazine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinSulfasalazine may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Sulfasalazine.Approved
CitalopramCitalopram may increase the antiplatelet activities of Sulfasalazine.Approved
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Sulfasalazine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Sulfasalazine.Approved, Investigational
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Sulfasalazine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Clonixin.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Sulfasalazine.Approved
CloprednolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cloprednol.Experimental
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Sulfasalazine.Vet Approved
CloranololSulfasalazine may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Sulfasalazine.Experimental
ClorindioneSulfasalazine may increase the anticoagulant activities of Clorindione.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sulfasalazine.Approved
CobicistatThe serum concentration of Sulfasalazine can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Sulfasalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColistimethateThe risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Sulfasalazine.Approved, Vet Approved
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Sulfasalazine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Sulfasalazine.Approved, Investigational
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with Sulfasalazine.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Sulfasalazine.Approved, Investigational
CortivazolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cortivazol.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Sulfasalazine.Approved
CryptenamineThe therapeutic efficacy of Cryptenamine can be decreased when used in combination with Sulfasalazine.Approved
CyclopentamineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cyclopentamine.Withdrawn
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Sulfasalazine.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Sulfasalazine.Approved, Investigational
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Sulfasalazine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Sulfasalazine.Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Sulfasalazine.Experimental
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Sulfasalazine.Approved, Investigational
Dabigatran etexilateThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Sulfasalazine.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Sulfasalazine.Approved, Investigational
DaclatasvirThe serum concentration of Sulfasalazine can be increased when it is combined with Daclatasvir.Approved, Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Sulfasalazine.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Sulfasalazine.Approved, Investigational
DaidzinThe serum concentration of Sulfasalazine can be increased when it is combined with Daidzin.Experimental
DalteparinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Dalteparin.Approved
DanaparoidThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Danaparoid.Approved, Withdrawn
DapagliflozinSulfasalazine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineDapoxetine may increase the antiplatelet activities of Sulfasalazine.Investigational
DarexabanThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Darexaban.Investigational
DasabuvirThe serum concentration of Sulfasalazine can be increased when it is combined with Dasabuvir.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with Sulfasalazine.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Sulfasalazine.Approved
DebrisoquinThe therapeutic efficacy of Debrisoquin can be decreased when used in combination with Sulfasalazine.Approved, Investigational
DecitabineThe risk or severity of adverse effects can be increased when Decitabine is combined with Sulfasalazine.Approved, Investigational
DeferasiroxThe risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Sulfasalazine is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Sulfasalazine.Approved, Investigational
DelafloxacinThe serum concentration of Delafloxacin can be increased when it is combined with Sulfasalazine.Approved, Investigational
DelaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Delapril.Investigational
DenosumabThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Sulfasalazine.Investigational
DersalazineThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Sulfasalazine is combined with Dersalazine.Investigational
DeserpidineThe therapeutic efficacy of Deserpidine can be decreased when used in combination with Sulfasalazine.Approved
DesirudinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Desirudin.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Sulfasalazine.Approved
DesmopressinThe risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Sulfasalazine is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Desoximetasone.Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Sulfasalazine.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Sulfasalazine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of bleeding and gastrointestinal bleeding can be increased when Sulfasalazine is combined with Dexketoprofen.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Sulfasalazine.Experimental
DexrazoxaneThe risk or severity of adverse effects can be increased when Dexrazoxane is combined with Sulfasalazine.Approved, Withdrawn
DextranThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Dextran.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Diazoxide can be decreased when used in combination with Sulfasalazine.Approved
DibekacinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Dibekacin.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Sulfasalazine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Diclofenamide.Approved, Investigational
DicoumarolSulfasalazine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylnorspermineThe therapeutic efficacy of Diethylnorspermine can be decreased when used in combination with Sulfasalazine.Investigational
DiethylstilbestrolThe serum concentration of Sulfasalazine can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Diflorasone.Approved
DifloxacinSulfasalazine may increase the neuroexcitatory activities of Difloxacin.Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Sulfasalazine.Approved, Investigational
DigoxinSulfasalazine may decrease the excretion rate of Digoxin which could result in a higher serum level.Approved
DihydralazineThe therapeutic efficacy of Dihydralazine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
DihydrostreptomycinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Sulfasalazine.Approved, Investigational
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Sulfasalazine.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Sulfasalazine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Sulfasalazine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Sulfasalazine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Sulfasalazine.Approved, Investigational
DiphenadioneSulfasalazine may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Dipyridamole.Approved
DisopyramideSulfasalazine may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Ditazole.Approved, Withdrawn
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sulfasalazine.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Sulfasalazine.Approved
DorzolamideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dorzolamide.Approved
DovitinibThe serum concentration of Sulfasalazine can be increased when it is combined with Dovitinib.Investigational
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Sulfasalazine.Approved
DoxifluridineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Sulfasalazine.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Sulfasalazine.Approved, Investigational
DronabinolThe serum concentration of Sulfasalazine can be increased when it is combined with Dronabinol.Approved, Illicit
DrospirenoneThe risk or severity of hyperkalemia can be increased when Sulfasalazine is combined with Drospirenone.Approved
Drotrecogin alfaThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Droxicam.Withdrawn
DulaglutideSulfasalazine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineDuloxetine may increase the antiplatelet activities of Sulfasalazine.Approved
DutogliptinSulfasalazine may increase the hypoglycemic activities of Dutogliptin.Investigational
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Sulfasalazine.Approved, Investigational
Edetic AcidThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Edetic Acid.Approved, Vet Approved
EdoxabanThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Edoxaban.Approved
EfalizumabThe risk or severity of adverse effects can be increased when Efalizumab is combined with Sulfasalazine.Approved, Investigational
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
ElacridarThe serum concentration of Sulfasalazine can be increased when it is combined with Elacridar.Investigational
EltrombopagThe serum concentration of Sulfasalazine can be increased when it is combined with Eltrombopag.Approved
EmpagliflozinSulfasalazine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Enalaprilat.Approved
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Sulfasalazine.Approved, Investigational
EndralazineThe therapeutic efficacy of Endralazine can be decreased when used in combination with Sulfasalazine.Experimental
EnglitazoneSulfasalazine may increase the hypoglycemic activities of Englitazone.Experimental
EnoxacinSulfasalazine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Sulfasalazine.Experimental
EpanololSulfasalazine may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Epirizole.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Sulfasalazine.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Sulfasalazine.Experimental
EplerenoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Sulfasalazine.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Sulfasalazine.Approved, Investigational
EribulinThe risk or severity of adverse effects can be increased when Eribulin is combined with Sulfasalazine.Approved, Investigational
ErlotinibThe serum concentration of Sulfasalazine can be increased when it is combined with Erlotinib.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Sulfasalazine.Approved, Investigational
EsatenololSulfasalazine may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Sulfasalazine.Approved, Investigational
EsmololSulfasalazine may decrease the antihypertensive activities of Esmolol.Approved
EstradiolThe serum concentration of Sulfasalazine can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Sulfasalazine can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Sulfasalazine can be increased when it is combined with Estradiol benzoate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Sulfasalazine can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Sulfasalazine can be increased when it is combined with Estradiol dienanthate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Sulfasalazine can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with Sulfasalazine.Approved, Investigational
EstroneThe serum concentration of Sulfasalazine can be increased when it is combined with Estrone.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sulfasalazine.Approved, Investigational
EtanerceptThe risk or severity of neutropenia can be increased when Etanercept is combined with Sulfasalazine.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ethenzamide.Experimental
EthoxzolamideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateSulfasalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Sulfasalazine.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etofenamate.Approved, Investigational
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Sulfasalazine.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Etoricoxib.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Sulfasalazine.Approved
EvogliptinSulfasalazine may increase the hypoglycemic activities of Evogliptin.Investigational
ExenatideSulfasalazine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzetimibeThe serum concentration of Sulfasalazine can be increased when it is combined with Ezetimibe.Approved
FelbinacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Felbinac.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fenbufen.Approved
FenoldopamThe therapeutic efficacy of Fenoldopam can be decreased when used in combination with Sulfasalazine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Sulfasalazine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Sulfasalazine.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Feprazone.Experimental
Ferulic acidThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Ferulic acid.Experimental
FibrinolysinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Fibrinolysin.Investigational
FimasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Sulfasalazine.Approved, Investigational
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Sulfasalazine.Approved, Investigational
FirocoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Firocoxib.Experimental, Vet Approved
FleroxacinSulfasalazine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Floctafenine.Approved, Withdrawn
FlomoxefThe risk or severity of nephrotoxicity can be increased when Flomoxef is combined with Sulfasalazine.Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Sulfasalazine.Approved
FlucloroloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluclorolone.Experimental
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Sulfasalazine.Approved, Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Sulfasalazine.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Sulfasalazine.Approved, Investigational
FluindioneSulfasalazine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineSulfasalazine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluocinonide.Approved, Investigational
FluocortinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluocortin.Experimental
FluocortoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluorometholone.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Sulfasalazine.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Sulfasalazine.Approved, Vet Approved
FluperoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluperolone.Experimental
FluprednideneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Sulfasalazine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Sulfasalazine.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fluticasone propionate.Approved
FluvastatinThe excretion of Fluvastatin can be decreased when combined with Sulfasalazine.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Sulfasalazine.Approved, Investigational
Folic AcidThe serum concentration of Folic Acid can be decreased when it is combined with Sulfasalazine.Approved, Nutraceutical, Vet Approved
FondaparinuxThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Fondaparinux.Approved, Investigational
ForasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Forasartan is combined with Sulfasalazine.Experimental
FormocortalThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Formocortal.Experimental
FoscarnetThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Foscarnet.Approved
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Fosinopril.Approved
FosinoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Fosinoprilat.Experimental
FostamatinibThe serum concentration of Sulfasalazine can be increased when it is combined with Fostamatinib.Approved, Investigational
FramycetinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Framycetin.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Sulfasalazine.Approved, Vet Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Sulfasalazine.Investigational
GabexateThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Gabexate.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Gallium nitrate is combined with Sulfasalazine.Approved, Investigational
GarenoxacinSulfasalazine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinSulfasalazine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Sulfasalazine.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Sulfasalazine.Approved
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Sulfasalazine.Approved, Withdrawn
GemifloxacinSulfasalazine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GemigliptinSulfasalazine may increase the hypoglycemic activities of Gemigliptin.Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Sulfasalazine.Approved, Investigational
GeneticinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Geneticin.Experimental
GenisteinThe serum concentration of Sulfasalazine can be increased when it is combined with Genistein.Investigational
GentamicinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with GENTAMICIN C1A.Experimental
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Sulfasalazine.Investigational
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Sulfasalazine.Approved, Investigational, Nutraceutical
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Sulfasalazine.Experimental
GlatiramerThe risk or severity of adverse effects can be increased when Glatiramer is combined with Sulfasalazine.Approved, Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Sulfasalazine.Approved, Investigational
GlibornurideSulfasalazine may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideSulfasalazine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideSulfasalazine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideSulfasalazine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneSulfasalazine may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideSulfasalazine may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideSulfasalazine may increase the hypoglycemic activities of Glyburide.Approved
GlycodiazineSulfasalazine may increase the hypoglycemic activities of Glycodiazine.Approved, Investigational
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Sulfasalazine.Approved
GosogliptinSulfasalazine may increase the hypoglycemic activities of Gosogliptin.Investigational
GrepafloxacinSulfasalazine may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Guacetisal.Experimental
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Sulfasalazine.Approved, Investigational
GuanadrelThe therapeutic efficacy of Guanadrel can be decreased when used in combination with Sulfasalazine.Approved
GuanazodineThe therapeutic efficacy of Guanazodine can be decreased when used in combination with Sulfasalazine.Experimental
GuanethidineThe therapeutic efficacy of Guanethidine can be decreased when used in combination with Sulfasalazine.Approved
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
GuanoclorThe therapeutic efficacy of Guanoclor can be decreased when used in combination with Sulfasalazine.Experimental
GuanoxabenzThe therapeutic efficacy of Guanoxabenz can be decreased when used in combination with Sulfasalazine.Experimental
GuanoxanThe therapeutic efficacy of Guanoxan can be decreased when used in combination with Sulfasalazine.Experimental
Guar gumSulfasalazine may increase the hypoglycemic activities of Guar gum.Experimental
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Sulfasalazine.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Halcinonide.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Halometasone.Experimental
HaloperidolThe therapeutic efficacy of Haloperidol can be increased when used in combination with Sulfasalazine.Approved
HeparinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Heparin.Approved, Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Sulfasalazine.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Sulfasalazine.Approved, Withdrawn
HesperetinThe serum concentration of Sulfasalazine can be increased when it is combined with Hesperetin.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hexamethonium.Experimental
Human rabies virus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Sulfasalazine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Sulfasalazine.Approved, Investigational
HydralazineSulfasalazine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Sulfasalazine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Sulfasalazine.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydrocortisone valerate.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Sulfasalazine.Approved, Investigational
Hydrolyzed CephalothinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Hydrolyzed Cephalothin.Experimental
HydroxychloroquineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Hydroxychloroquine.Approved
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Sulfasalazine.Investigational
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Sulfasalazine.Approved
Hygromycin BThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Sulfasalazine.Investigational
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Sulfasalazine.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sulfasalazine.Approved
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Sulfasalazine.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibuproxam.Withdrawn
IcosapentThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Icosapent.Approved, Nutraceutical
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Sulfasalazine.Approved, Investigational, Nutraceutical
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Sulfasalazine.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Sulfasalazine.Approved
IdraparinuxThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Idraparinux.Investigational
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Sulfasalazine.Investigational
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Sulfasalazine.Approved
IloprostThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Iloprost.Approved, Investigational
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Sulfasalazine.Approved
ImidaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Imidazole salicylate.Experimental
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Sulfasalazine.Approved, Investigational
Incadronic acidThe risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Incadronic acid.Approved, Investigational
IndalpineIndalpine may increase the antiplatelet activities of Sulfasalazine.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Sulfasalazine.Approved
IndenololSulfasalazine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Sulfasalazine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Indoprofen.Withdrawn
IndoraminThe therapeutic efficacy of Indoramin can be decreased when used in combination with Sulfasalazine.Withdrawn
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Sulfasalazine.Approved
Influenza Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Influenza Vaccine (Live/Attenuated) is combined with Sulfasalazine.Approved
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Sulfasalazine.Investigational
Insulin AspartSulfasalazine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin BeefSulfasalazine may increase the hypoglycemic activities of Insulin Beef.Approved
Insulin DegludecSulfasalazine may increase the hypoglycemic activities of Insulin Degludec.Approved
Insulin DetemirSulfasalazine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineSulfasalazine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineSulfasalazine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanSulfasalazine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproSulfasalazine may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin peglisproSulfasalazine may increase the hypoglycemic activities of Insulin peglispro.Investigational
Insulin PorkSulfasalazine may increase the hypoglycemic activities of Insulin Pork.Approved
Interferon alfa-n3The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Sulfasalazine.Approved, Investigational
Interferon alfacon-1The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Sulfasalazine.Approved, Investigational
IrbesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Sulfasalazine.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Sulfasalazine.Approved, Investigational
IsepamicinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Isepamicin.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Isoxicam.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Sulfasalazine.Approved, Investigational, Vet Approved
IxabepiloneThe risk or severity of adverse effects can be increased when Ixabepilone is combined with Sulfasalazine.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Sulfasalazine.Approved
KanamycinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Kanamycin.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Kebuzone.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Sulfasalazine.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Sulfasalazine.Approved
KRP-104Sulfasalazine may increase the hypoglycemic activities of KRP-104.Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Sulfasalazine.Approved, Investigational, Nutraceutical
LabetalolSulfasalazine may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Sulfasalazine.Approved, Investigational
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Sulfasalazine.Experimental
LandiololSulfasalazine may decrease the antihypertensive activities of Landiolol.Investigational
LatamoxefThe risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Sulfasalazine.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Sulfasalazine.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Sulfasalazine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Sulfasalazine.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Sulfasalazine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Sulfasalazine.Approved, Investigational
LepirudinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
LetaxabanThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Letaxaban.Investigational
LetermovirThe serum concentration of Sulfasalazine can be increased when it is combined with Letermovir.Approved, Investigational
LevobetaxololSulfasalazine may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololSulfasalazine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinSulfasalazine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Sulfasalazine.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Sulfasalazine.Approved, Investigational
LinagliptinSulfasalazine may increase the hypoglycemic activities of Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Sulfasalazine.Approved, Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Sulfasalazine.Experimental
LiraglutideSulfasalazine may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Lisinopril.Approved, Investigational
Lithium cationSulfasalazine may decrease the excretion rate of Lithium cation which could result in a higher serum level.Experimental
LixisenatideSulfasalazine may increase the hypoglycemic activities of Lixisenatide.Approved
LobeglitazoneSulfasalazine may increase the hypoglycemic activities of Lobeglitazone.Approved, Investigational
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
LomefloxacinSulfasalazine may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Sulfasalazine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Lonazolac.Experimental
LoracarbefThe risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Sulfasalazine.Investigational, Withdrawn
LornoxicamThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Sulfasalazine.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Loteprednol.Approved
LovastatinThe excretion of Lovastatin can be decreased when combined with Sulfasalazine.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Sulfasalazine.Vet Approved
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Sulfasalazine.Approved, Investigational
MacitentanThe therapeutic efficacy of Macitentan can be decreased when used in combination with Sulfasalazine.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Magnesium salicylate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
MannitolThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Sulfasalazine.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mecamylamine.Approved, Investigational
MecaserminSulfasalazine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Sulfasalazine.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Meclofenamic acid.Approved, Vet Approved
Medical CannabisThe serum concentration of Sulfasalazine can be increased when it is combined with Medical Cannabis.Experimental, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Sulfasalazine.Approved
MelagatranThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Meloxicam.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Sulfasalazine.Approved
MepindololSulfasalazine may decrease the antihypertensive activities of Mepindolol.Experimental
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with Sulfasalazine.Approved, Investigational
MeprednisoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Meprednisone.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Sulfasalazine.Approved
MesalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mesalazine.Approved
MetahexamideSulfasalazine may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Metamizole.Approved, Investigational, Withdrawn
MetforminSulfasalazine may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Methazolamide.Approved
MethenamineThe risk or severity of adverse effects can be increased when Methenamine is combined with Sulfasalazine.Approved, Vet Approved
MethimazoleThe risk or severity of adverse effects can be increased when Methimazole is combined with Sulfasalazine.Approved
MethoserpidineThe therapeutic efficacy of Methoserpidine can be decreased when used in combination with Sulfasalazine.Experimental
MethotrexateSulfasalazine may increase the hepatotoxic activities of Methotrexate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Sulfasalazine.Approved
Methyl salicylateThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Sulfasalazine is combined with Methyl salicylate.Approved, Vet Approved
MethyldopaThe therapeutic efficacy of Methyldopa can be decreased when used in combination with Sulfasalazine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Sulfasalazine.Approved, Vet Approved
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Sulfasalazine.Experimental
MetipranololSulfasalazine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Sulfasalazine.Approved
MetoprololSulfasalazine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetyrosineThe therapeutic efficacy of Metyrosine can be decreased when used in combination with Sulfasalazine.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Sulfasalazine.Investigational, Withdrawn
MicronomicinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Micronomicin.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Sulfasalazine.Approved, Experimental
MifepristoneSulfasalazine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolSulfasalazine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranMilnacipran may increase the antiplatelet activities of Sulfasalazine.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Sulfasalazine.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Sulfasalazine.Approved
MitiglinideSulfasalazine may increase the hypoglycemic activities of Mitiglinide.Approved, Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Sulfasalazine.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Sulfasalazine.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Sulfasalazine.Investigational
MoexiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mometasone.Approved, Vet Approved
Mometasone furoateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mometasone furoate.Approved, Vet Approved
Monopotassium phosphateThe serum concentration of Sulfasalazine can be increased when it is combined with Monopotassium phosphate.Approved, Investigational, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Morniflumate.Approved
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Sulfasalazine.Approved, Investigational, Vet Approved
MoxifloxacinSulfasalazine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Sulfasalazine.Approved, Investigational
MuzolimineThe therapeutic efficacy of Muzolimine can be decreased when used in combination with Sulfasalazine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Sulfasalazine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Sulfasalazine.Approved
NabiximolsThe serum concentration of Sulfasalazine can be increased when it is combined with Nabiximols.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Sulfasalazine.Approved
NadololSulfasalazine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Nadroparin.Approved, Investigational
NafamostatThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Sulfasalazine.Investigational
Nalidixic AcidSulfasalazine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Sulfasalazine.Approved, Vet Approved
NaringeninThe serum concentration of Sulfasalazine can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Sulfasalazine.Approved, Investigational
NateglinideSulfasalazine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NBI-6024Sulfasalazine may increase the hypoglycemic activities of NBI-6024.Investigational
NeamineThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Neamine.Experimental
NebivololSulfasalazine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Sulfasalazine.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with Sulfasalazine.Approved, Investigational
NelfinavirThe serum concentration of Sulfasalazine can be increased when it is combined with Nelfinavir.Approved
NemonoxacinSulfasalazine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Sulfasalazine.Approved, Investigational
NetilmicinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Netilmicin.Approved, Investigational
NetoglitazoneSulfasalazine may increase the hypoglycemic activities of Netoglitazone.Experimental
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
NicorandilThe therapeutic efficacy of Nicorandil can be decreased when used in combination with Sulfasalazine.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nicotine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Sulfasalazine.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Sulfasalazine.Approved, Investigational
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Sulfasalazine.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nitroaspirin.Investigational
NitrofurantoinThe serum concentration of Nitrofurantoin can be increased when it is combined with Sulfasalazine.Approved, Vet Approved
NitroprussideThe therapeutic efficacy of Nitroprusside can be decreased when used in combination with Sulfasalazine.Approved, Investigational
NN344Sulfasalazine may increase the hypoglycemic activities of NN344.Investigational
NorfloxacinSulfasalazine may increase the neuroexcitatory activities of Norfloxacin.Approved
NovobiocinThe serum concentration of Sulfasalazine can be increased when it is combined with Novobiocin.Approved, Investigational, Vet Approved
NS-398The risk or severity of adverse effects can be increased when Sulfasalazine is combined with NS-398.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sulfasalazine.Approved, Investigational
OcrelizumabThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ocrelizumab.Approved, Investigational
OfloxacinSulfasalazine may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe risk or severity of adverse effects can be increased when Olaparib is combined with Sulfasalazine.Approved
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Sulfasalazine.Experimental, Investigational
OlmesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Sulfasalazine.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Omapatrilat.Investigational
OmarigliptinSulfasalazine may increase the hypoglycemic activities of Omarigliptin.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Sulfasalazine.Approved, Investigational
OrbifloxacinSulfasalazine may increase the neuroexcitatory activities of Orbifloxacin.Vet Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Sulfasalazine.Approved
OtamixabanThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Sulfasalazine.Approved
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Sulfasalazine.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Oxaprozin.Approved
Oxolinic acidSulfasalazine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololSulfasalazine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sulfasalazine.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with Sulfasalazine.Approved, Investigational
PamidronateThe risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Pamidronate.Approved
PanobinostatThe risk or severity of adverse effects can be increased when Panobinostat is combined with Sulfasalazine.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Parecoxib.Approved
PargylineThe therapeutic efficacy of Pargyline can be decreased when used in combination with Sulfasalazine.Approved
ParitaprevirThe serum concentration of Sulfasalazine can be increased when it is combined with Paritaprevir.Approved, Investigational
ParnaparinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Parnaparin.Approved, Investigational
ParomomycinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Sulfasalazine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Sulfasalazine.Approved
PazufloxacinSulfasalazine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinSulfasalazine may increase the neuroexcitatory activities of Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with Sulfasalazine.Approved, Investigational
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Sulfasalazine.Approved, Investigational
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Sulfasalazine.Approved
PemetrexedThe serum concentration of Pemetrexed can be increased when it is combined with Sulfasalazine.Approved, Investigational
PenbutololSulfasalazine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineSulfasalazine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentoliniumThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pentolinium.Approved
Pentosan PolysulfateThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Pentosan Polysulfate.Approved
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Sulfasalazine.Approved, Investigational
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Sulfasalazine.Approved, Investigational
PerindoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Perindopril.Approved
PerindoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Perindoprilat.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Sulfasalazine.Experimental
PhenforminSulfasalazine may increase the hypoglycemic activities of Phenformin.Approved, Investigational, Withdrawn
PhenindioneSulfasalazine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenoxybenzamineThe therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Sulfasalazine.Approved
PhenprocoumonSulfasalazine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolamineThe therapeutic efficacy of Phentolamine can be decreased when used in combination with Sulfasalazine.Approved
Phenyl aminosalicylateThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Sulfasalazine is combined with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Phenylbutazone.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Sulfasalazine.Approved, Investigational
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Sulfasalazine.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Sulfasalazine.Approved, Investigational
PinacidilThe therapeutic efficacy of Pinacidil can be decreased when used in combination with Sulfasalazine.Approved
PindololSulfasalazine may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PioglitazoneSulfasalazine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
Pipemidic acidSulfasalazine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Sulfasalazine.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Sulfasalazine.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Sulfasalazine.Approved, Investigational
Piromidic acidSulfasalazine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Sulfasalazine.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Sulfasalazine.Approved
PitolisantThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pitolisant.Approved, Investigational
PlazomicinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Plazomicin.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Sulfasalazine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Sulfasalazine.Approved
PonatinibThe risk or severity of adverse effects can be increased when Ponatinib is combined with Sulfasalazine.Approved, Investigational
Potassium CitrateThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PractololSulfasalazine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Sulfasalazine.Approved, Investigational
PramlintideSulfasalazine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pranoprofen.Experimental, Investigational
PrasugrelThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Prasugrel.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Sulfasalazine.Approved
PrazosinThe therapeutic efficacy of Prazosin can be decreased when used in combination with Sulfasalazine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Sulfasalazine.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Sulfasalazine.Approved, Vet Approved
PrednylideneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Prednylidene.Experimental
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Sulfasalazine.Approved, Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Sulfasalazine.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Propacetamol.Approved, Investigational
PropafenoneSulfasalazine may decrease the antihypertensive activities of Propafenone.Approved
PropranololSulfasalazine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropylthiouracilThe risk or severity of adverse effects can be increased when Propylthiouracil is combined with Sulfasalazine.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Proquazone.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Sulfasalazine.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Sulfasalazine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Sulfasalazine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Sulfasalazine.Vet Approved
Protein CThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Protein C.Approved
Protein S humanThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Protein S human.Approved
ProtocatechualdehydeThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Protocatechualdehyde.Approved
PrulifloxacinSulfasalazine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PuromycinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Puromycin.Experimental
QuercetinThe serum concentration of Sulfasalazine can be increased when it is combined with Quercetin.Experimental, Investigational
QuinaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Quinapril.Approved, Investigational
QuinaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Quinaprilat.Experimental
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Sulfasalazine.Approved
QuinineSulfasalazine may increase the hypoglycemic activities of Quinine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Sulfasalazine.Approved, Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Raltitrexed is combined with Sulfasalazine.Approved, Investigational
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Sulfasalazine.Investigational
RamiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Ramipril.Approved
RamiprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Ramiprilat.Experimental
RegorafenibThe serum concentration of Sulfasalazine can be increased when it is combined with Regorafenib.Approved
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Sulfasalazine.Investigational
RemikirenThe therapeutic efficacy of Remikiren can be decreased when used in combination with Sulfasalazine.Approved
RepaglinideSulfasalazine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Rescinnamine.Approved
ReserpineThe therapeutic efficacy of Reserpine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Sulfasalazine.Approved, Experimental, Investigational
ReteplaseThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Reteplase.Approved, Investigational
ReviparinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Reviparin.Approved, Investigational
RibostamycinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Ribostamycin.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Sulfasalazine.Approved
RilmenidineThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Sulfasalazine.Approved, Investigational
RilpivirineThe serum concentration of Sulfasalazine can be increased when it is combined with Rilpivirine.Approved
RiluzoleThe serum concentration of Riluzole can be increased when it is combined with Sulfasalazine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Sulfasalazine.Investigational
RiociguatThe therapeutic efficacy of Riociguat can be decreased when used in combination with Sulfasalazine.Approved
RisedronateThe risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Risedronate.Approved, Investigational
RitanserinRitanserin may increase the antiplatelet activities of Sulfasalazine.Investigational
RitonavirThe serum concentration of Sulfasalazine can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Sulfasalazine.Approved
RivaroxabanThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Rivaroxaban.Approved
RivoglitazoneSulfasalazine may increase the hypoglycemic activities of Rivoglitazone.Experimental, Investigational
RobenacoxibThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Robenacoxib.Experimental, Vet Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Sulfasalazine.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Sulfasalazine.Approved
RosiglitazoneSulfasalazine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosoxacinSulfasalazine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Sulfasalazine.Approved
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Sulfasalazine.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Sulfasalazine.Approved, Investigational
RufloxacinSulfasalazine may increase the neuroexcitatory activities of Rufloxacin.Experimental
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Sulfasalazine.Approved
SafinamideThe serum concentration of Sulfasalazine can be increased when it is combined with Safinamide.Approved, Investigational
SalicylamideThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salicylic acid.Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Sulfasalazine.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of infection can be increased when Salmonella typhi Ty21a live antigen is combined with Sulfasalazine.Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Sulfasalazine.Approved
SalsalateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Salsalate.Approved
SaprisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Sulfasalazine.Experimental
SaquinavirThe serum concentration of Sulfasalazine can be increased when it is combined with Saquinavir.Approved, Investigational
SarafloxacinSulfasalazine may increase the neuroexcitatory activities of Sarafloxacin.Vet Approved, Withdrawn
SaralasinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saralasin is combined with Sulfasalazine.Investigational
SarilumabThe risk or severity of adverse effects can be increased when Sarilumab is combined with Sulfasalazine.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Sulfasalazine.Investigational
SaruplaseThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Saruplase.Experimental
SaxagliptinSulfasalazine may increase the hypoglycemic activities of Saxagliptin.Approved
SC-236The risk or severity of adverse effects can be increased when Sulfasalazine is combined with SC-236.Experimental, Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Sulfasalazine.Approved
SelexipagThe therapeutic efficacy of Selexipag can be decreased when used in combination with Sulfasalazine.Approved
SemaglutideSulfasalazine may increase the hypoglycemic activities of Semaglutide.Approved, Investigational
SertralineSertraline may increase the antiplatelet activities of Sulfasalazine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sulfasalazine.Approved, Vet Approved
SibutramineSibutramine may increase the antiplatelet activities of Sulfasalazine.Approved, Illicit, Investigational, Withdrawn
SiltuximabThe risk or severity of adverse effects can be increased when Siltuximab is combined with Sulfasalazine.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Sulfasalazine.Approved
SimvastatinThe excretion of Simvastatin can be decreased when combined with Sulfasalazine.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sulfasalazine.Approved, Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Sulfasalazine.Approved, Investigational
SisomicinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Sisomicin.Investigational
SitafloxacinSulfasalazine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitagliptinSulfasalazine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanThe therapeutic efficacy of Sitaxentan can be decreased when used in combination with Sulfasalazine.Approved, Investigational, Withdrawn
Sodium CitrateThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Sulfasalazine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Sulfasalazine.Approved
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Sulfasalazine.Approved, Investigational
SotagliflozinSulfasalazine may increase the hypoglycemic activities of Sotagliflozin.Investigational
SotalolSulfasalazine may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinSulfasalazine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Spironolactone.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Sulfasalazine.Investigational
SteproninThe risk or severity of adverse effects can be increased when Stepronin is combined with Sulfasalazine.Approved
StreptokinaseThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Streptokinase.Approved, Investigational
StreptomycinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Streptomycin.Approved, Vet Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Sulfasalazine.Approved, Investigational
SulfadiazineSulfasalazine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleSulfasalazine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfinpyrazoneThe risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Sulfasalazine.Approved
SulfisoxazoleSulfasalazine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Sulfasalazine.Approved, Investigational
SulodexideThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Sulfasalazine.Investigational
SunitinibThe risk or severity of adverse effects can be increased when Sunitinib is combined with Sulfasalazine.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Suxibuzone.Experimental
TacrolimusThe risk or severity of renal failure can be increased when Sulfasalazine is combined with Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Sulfasalazine.Approved
TalinololSulfasalazine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Talniflumate.Approved
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Sulfasalazine.Approved
TasosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Sulfasalazine.Approved
TaspoglutideSulfasalazine may increase the hypoglycemic activities of Taspoglutide.Investigational
Taurocholic AcidThe serum concentration of Sulfasalazine can be increased when it is combined with Taurocholic Acid.Experimental
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Sulfasalazine.Investigational
Technetium Tc-99m ciprofloxacinSulfasalazine may increase the neuroexcitatory activities of Technetium Tc-99m ciprofloxacin.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tedizolid phosphate is combined with Sulfasalazine.Approved
TelmisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Sulfasalazine.Approved, Investigational
TemafloxacinSulfasalazine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Temocapril.Experimental, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Sulfasalazine.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Sulfasalazine.Approved
TenecteplaseThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Tenecteplase.Approved
TeneligliptinSulfasalazine may increase the hypoglycemic activities of Teneligliptin.Investigational
TenidapThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tenidap.Experimental
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Sulfasalazine.Approved
TenofovirThe serum concentration of Tenofovir can be increased when it is combined with Sulfasalazine.Experimental, Investigational
Tenofovir alafenamideThe serum concentration of Tenofovir alafenamide can be increased when it is combined with Sulfasalazine.Approved
Tenofovir disoproxilSulfasalazine may decrease the excretion rate of Tenofovir disoproxil which could result in a higher serum level.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Sulfasalazine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Sulfasalazine.Vet Approved
TerazosinThe therapeutic efficacy of Terazosin can be decreased when used in combination with Sulfasalazine.Approved
TeriflunomideThe serum concentration of Sulfasalazine can be increased when it is combined with Teriflunomide.Approved
TertatololSulfasalazine may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Sulfasalazine.Investigational
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Sulfasalazine.Approved, Investigational
Testosterone cypionateThe serum concentration of Testosterone cypionate can be increased when it is combined with Sulfasalazine.Approved
Testosterone enanthateThe serum concentration of Testosterone enanthate can be increased when it is combined with Sulfasalazine.Approved
Testosterone undecanoateThe serum concentration of Testosterone undecanoate can be increased when it is combined with Sulfasalazine.Approved, Investigational
TetraethylammoniumThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tetraethylammonium.Experimental, Investigational
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Sulfasalazine.Investigational
TetrandrineThe risk or severity of adverse effects can be increased when Tetrandrine is combined with Sulfasalazine.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Sulfasalazine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Sulfasalazine.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Sulfasalazine.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tiaprofenic acid.Approved
TicagrelorThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Sulfasalazine.Approved
TicrynafenThe therapeutic efficacy of Ticrynafen can be decreased when used in combination with Sulfasalazine.Withdrawn
Tiludronic acidThe risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololSulfasalazine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tinoridine.Investigational
TinzaparinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Tinzaparin.Approved
TioclomarolSulfasalazine may increase the anticoagulant activities of Tioclomarol.Experimental
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Sulfasalazine.Approved
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Sulfasalazine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tixocortol.Approved, Withdrawn
TobramycinThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Tobramycin.Approved, Investigational
TocilizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Sulfasalazine.Approved
TocopherylquinoneThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Tocopherylquinone.Experimental, Investigational
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Sulfasalazine.Approved, Investigational
TolazamideSulfasalazine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineThe therapeutic efficacy of Tolazoline can be decreased when used in combination with Sulfasalazine.Approved, Vet Approved
TolbutamideSulfasalazine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Sulfasalazine.Approved
TolonidineThe therapeutic efficacy of Tolonidine can be decreased when used in combination with Sulfasalazine.Experimental
TopiroxostatThe serum concentration of Sulfasalazine can be increased when it is combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Sulfasalazine.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Sulfasalazine.Approved
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Sulfasalazine.Approved, Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with Sulfasalazine.Approved, Investigational
TrandolaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Sulfasalazine.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Sulfasalazine.Approved
TrastuzumabThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Sulfasalazine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Sulfasalazine.Approved
TrazodoneTrazodone may increase the antiplatelet activities of Sulfasalazine.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Sulfasalazine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Sulfasalazine.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Sulfasalazine.Approved, Vet Approved
TriamtereneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Sulfasalazine.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Trifluridine.Approved, Investigational
TriflusalThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Triflusal.Approved, Investigational
TrilostaneThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimazosinThe therapeutic efficacy of Trimazosin can be decreased when used in combination with Sulfasalazine.Experimental
TrimethaphanThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Trimethaphan.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Sulfasalazine.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Sulfasalazine.Investigational
TroglitazoneSulfasalazine may increase the hypoglycemic activities of Troglitazone.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Trolamine salicylate.Approved
TrovafloxacinSulfasalazine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Troxerutin.Investigational
TubocurarineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Tubocurarine.Approved
Typhoid VaccineThe therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Sulfasalazine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Sulfasalazine.Approved, Investigational
UrapidilThe therapeutic efficacy of Urapidil can be decreased when used in combination with Sulfasalazine.Investigational
UrokinaseThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Urokinase.Approved, Investigational, Withdrawn
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Sulfasalazine.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Sulfasalazine.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Sulfasalazine.Approved, Investigational
ValsartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Sulfasalazine.Approved, Investigational
VancomycinSulfasalazine may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VandetanibThe serum concentration of Sulfasalazine can be increased when it is combined with Vandetanib.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/Attenuated) is combined with Sulfasalazine.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Sulfasalazine.Approved
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Sulfasalazine.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Sulfasalazine.Approved, Investigational
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Sulfasalazine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Sulfasalazine.Approved, Investigational
VenlafaxineVenlafaxine may increase the antiplatelet activities of Sulfasalazine.Approved
VerapamilVerapamil may increase the anticoagulant activities of Sulfasalazine.Approved
Vibrio cholerae CVD 103-HgR strain live antigenThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Sulfasalazine.Approved, Investigational
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Sulfasalazine.Approved, Investigational
VilanterolThe risk or severity of adverse effects can be increased when Vilanterol is combined with Sulfasalazine.Approved
VildagliptinSulfasalazine may increase the hypoglycemic activities of Vildagliptin.Approved, Investigational
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Sulfasalazine.Approved
VincamineThe therapeutic efficacy of Vincamine can be decreased when used in combination with Sulfasalazine.Experimental
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Sulfasalazine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Sulfasalazine.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Sulfasalazine.Approved, Investigational
VismodegibThe serum concentration of Sulfasalazine can be increased when it is combined with Vismodegib.Approved, Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Sulfasalazine.Investigational
VogliboseSulfasalazine may increase the hypoglycemic activities of Voglibose.Approved, Investigational
VorapaxarThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Vorapaxar.Approved
VorinostatThe risk or severity of adverse effects can be increased when Vorinostat is combined with Sulfasalazine.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Sulfasalazine.Approved, Investigational
WarfarinSulfasalazine may increase the anticoagulant activities of Warfarin.Approved
WortmanninThe risk or severity of adverse effects can be increased when Wortmannin is combined with Sulfasalazine.Experimental
XimelagatranThe risk or severity of bleeding can be increased when Sulfasalazine is combined with Ximelagatran.Approved, Investigational, Withdrawn
XipamideThe therapeutic efficacy of Xipamide can be decreased when used in combination with Sulfasalazine.Experimental
Yellow Fever VaccineThe risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Sulfasalazine.Approved, Investigational
Yellow Fever VaccineThe therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Sulfasalazine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe risk or severity of adverse effects can be increased when Zidovudine is combined with Sulfasalazine.Approved
ZimelidineZimelidine may increase the antiplatelet activities of Sulfasalazine.Withdrawn
ZofenoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Zomepirac.Withdrawn
Food Interactions
  • May take Vitamin D.
  • Take with a full glass of water No iron, zinc or fluoride within 2 hours of taking this medication.
  • Take with food.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014933
KEGG Drug
D00448
KEGG Compound
C07316
PubChem Compound
5359476
PubChem Substance
46505451
ChemSpider
10605946
BindingDB
50103596
ChEBI
9334
ChEMBL
CHEMBL421
Therapeutic Targets Database
DAP000153
PharmGKB
PA451547
HET
SAS
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sulfasalazine
ATC Codes
A07EC01 — SulfasalazineG01AE10 — Combinations of sulfonamides
AHFS Codes
  • 08:12.20 — Sulfonamides
PDB Entries
13gs / 4j7x / 5acl
FDA label
Download (796 KB)
MSDS
Download (72.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1CompletedBasic ScienceAdministration, Oral / Magnetic Resonance Imaging (MRI) / Pharmacokinetics1
1CompletedBasic ScienceIntestinal Obstruction2
1CompletedBasic ScienceProphylaxis of acute chemotherapy induced nausea and vomiting1
2CompletedTreatmentRheumatoid Arthritis1
2Not Yet RecruitingTreatmentPrimary Sclerosing Cholangitis (PSC)1
2RecruitingTreatmentAnkylosing Spondylitis (AS)1
2TerminatedTreatmentPainful Neuropathy1
2Unknown StatusTreatmentModerate to Severe Active Axial Spondyloarthritis1
2, 3Unknown StatusTreatmentEarly Ankylosing Spondylitis1
3Active Not RecruitingSupportive CareDiarrhea / Gastrointestinal Complications / Unspecified Adult Solid Tumor, Protocol Specific1
3CompletedTreatmentRheumatoid Arthritis5
4Active Not RecruitingTreatmentRheumatoid Arthritis1
4CompletedTreatmentAnkylosing Spondylitis (AS)1
4CompletedTreatmentRheumatoid Arthritis2
4Not Yet RecruitingTreatmentAnkylosing Spondylitis (AS)1
4RecruitingTreatmentAnkylosing Spondylitis (AS)1
4RecruitingTreatmentCardiovascular Risk Factors / Endothelial Dysfunction / Rheumatoid Arthritis / Stiffness, Aortic1
4RecruitingTreatmentRheumatoid Arthritis4
4TerminatedTreatmentRheumatoid Arthritis, Juvenile1
Not AvailableCompletedBasic ScienceCoronary Artery Disease1
Not AvailableCompletedTreatmentAlcohol Dependence1
Not AvailableCompletedTreatmentNeoplasms, Brain1
Not AvailableCompletedTreatmentRheumatoid Arthritis1
Not AvailableRecruitingNot AvailableRheumatoid Arthritis1
Not AvailableRecruitingTreatmentRecurrence (Disease Attribute)1

Pharmacoeconomics

Manufacturers
  • Pharmacia and upjohn co
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • Solvay pharmaceuticals
  • Heritage pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Sandoz inc
  • Superpharm corp
Packagers
  • Amerisource Health Services Corp.
  • A-S Medication Solutions LLC
  • Carlisle Laboratories Inc.
  • Darby Dental Supply Co. Inc.
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Greenstone LLC
  • Kaiser Foundation Hospital
  • Kemwell AB
  • Major Pharmaceuticals
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mutual Pharmaceutical Co.
  • Nucare Pharmaceuticals Inc.
  • Patheon Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmacia Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Prepak Systems Inc.
  • Qualitest
  • Remedy Repack
  • Tya Pharmaceuticals
  • United Research Laboratories Inc.
  • Vintage Pharmaceuticals Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
Tablet, delayed releaseOral500 mg
SuspensionRectal3 g
EnemaRectal3 g
TabletOral500 mg
TabletOral500 mg/1
Tablet, delayed releaseOral500 mg/1
Prices
Unit descriptionCostUnit
Sulfasalazine powder2.14USD g
Azulfidine EN-tabs 500 mg Enteric Coated Tabs0.73USD tab
Azulfidine entab 500 mg0.69USD tablet
Azulfidine 500 mg tablet0.59USD tablet
Salazopyrin En-Tabs 500 mg Enteric-Coated Tablet0.45USD tablet
Sulfasalazine 500 mg Enteric Coated Tabs0.4USD tab
Pms-Sulfasalazine 500 mg Enteric-Coated Tablet0.34USD tablet
Salazopyrin 500 mg Tablet0.28USD tablet
Sulfasalazine 500 mg tablet0.25USD tablet
Sulfazine 500 mg tablet0.25USD tablet
Pms-Sulfasalazine 500 mg Tablet0.22USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)220 dec °CPhysProp
logP2.5Not Available
Caco2 permeability-6.33ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0464 mg/mLALOGPS
logP2.92ALOGPS
logP3.94ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)3.3ChemAxon
pKa (Strongest Basic)2.4ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area141.31 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.6 m3·mol-1ChemAxon
Polarizability39.69 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier-0.7294
Caco-2 permeable-0.6893
P-glycoprotein substrateNon-substrate0.8405
P-glycoprotein inhibitor INon-inhibitor0.9096
P-glycoprotein inhibitor IINon-inhibitor0.853
Renal organic cation transporterNon-inhibitor0.8956
CYP450 2C9 substrateNon-substrate0.6445
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7557
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.923
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8895
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.6468
BiodegradationNot ready biodegradable0.9472
Rat acute toxicity1.4383 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.939
hERG inhibition (predictor II)Non-inhibitor0.821
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-0239100000-5bf223e6e250eb77105a

Taxonomy

Description
This compound belongs to the class of organic compounds known as azobenzenes. These are organonitrogen aromatic compounds that contain a central azo group, where each nitrogen atom is conjugated to a benzene ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azobenzenes
Sub Class
Not Available
Direct Parent
Azobenzenes
Alternative Parents
Salicylic acids / Benzenesulfonamides / Benzenesulfonyl compounds / Benzoic acids / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / Pyridines and derivatives / Organosulfonamides / Imidolactams / Vinylogous acids
show 11 more
Substituents
Azobenzene / Benzenesulfonamide / Hydroxybenzoic acid / Salicylic acid or derivatives / Salicylic acid / Benzoic acid or derivatives / Benzoic acid / Benzenesulfonyl group / Benzoyl / 1-hydroxy-2-unsubstituted benzenoid
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
sulfonamide, azobenzenes, pyridines (CHEBI:9334)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Iron ion binding
Specific Function
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name
ALOX5
Uniprot ID
P09917
Uniprot Name
Arachidonate 5-lipoxygenase
Molecular Weight
77982.595 Da
References
  1. Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82. [PubMed:2882965]
  2. Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51. [PubMed:6428914]
  3. Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2. [PubMed:6131674]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8. [PubMed:14742690]
  2. Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94. [PubMed:12463455]
  3. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19. [PubMed:16855178]
  4. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6. [PubMed:12208114]
  5. Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7. [PubMed:9256165]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE...
Gene Name
PPARG
Uniprot ID
P37231
Uniprot Name
Peroxisome proliferator-activated receptor gamma
Molecular Weight
57619.58 Da
References
  1. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005 Apr 18;201(8):1205-15. Epub 2005 Apr 11. [PubMed:15824083]
  2. Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J: PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis. 2008 Jul;29(7):1407-14. doi: 10.1093/carcin/bgn118. Epub 2008 Jun 9. [PubMed:18544567]
  3. Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12. [PubMed:18077625]
  4. Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9. [PubMed:16939423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or oth...
Gene Name
CHUK
Uniprot ID
O15111
Uniprot Name
Inhibitor of nuclear factor kappa-B kinase subunit alpha
Molecular Weight
84638.88 Da
References
  1. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [PubMed:11054378]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or oth...
Gene Name
IKBKB
Uniprot ID
O14920
Uniprot Name
Inhibitor of nuclear factor kappa-B kinase subunit beta
Molecular Weight
86563.245 Da
References
  1. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [PubMed:11054378]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Cystine:glutamate antiporter activity
Specific Function
Sodium-independent, high-affinity exchange of anionic amino acids with high specificity for anionic form of cystine and glutamate.
Gene Name
SLC7A11
Uniprot ID
Q9UPY5
Uniprot Name
Cystine/glutamate transporter
Molecular Weight
55422.44 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Gout PW, Buckley AR, Simms CR, Bruchovsky N: Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia. 2001 Oct;15(10):1633-40. [PubMed:11587223]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Plays a major role in ketone body metabolism.
Gene Name
ACAT1
Uniprot ID
P24752
Uniprot Name
Acetyl-CoA acetyltransferase, mitochondrial
Molecular Weight
45199.2 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Faison LD, White HL: Sulfasalazine inhibits lyso-PAF: acetyl-COA acetyltransferase. Prostaglandins. 1992 Sep;44(3):245-9. [PubMed:1357724]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thromboxane-a synthase activity
Specific Function
Not Available
Gene Name
TBXAS1
Uniprot ID
P24557
Uniprot Name
Thromboxane-A synthase
Molecular Weight
60517.69 Da
References
  1. Stenson WF, Lobos E: Inhibition of platelet thromboxane synthetase by sulfasalazine. Biochem Pharmacol. 1983 Jul 15;32(14):2205-9. [PubMed:6135423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor binding
Specific Function
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides, this releases glycerophospholipids and arachidonic acid that serve as the precursors of signal molecules.
Gene Name
PLA2G1B
Uniprot ID
P04054
Uniprot Name
Phospholipase A2
Molecular Weight
16359.535 Da
References
  1. Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7. [PubMed:9256165]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB: High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos. 2010 Apr;38(4):705-14. doi: 10.1124/dmd.109.028886. Epub 2010 Jan 13. [PubMed:20071452]
  2. Shukla S, Zaher H, Hartz A, Bauer B, Ware JA, Ambudkar SV: Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7. doi: 10.1007/s11095-008-9735-8. Epub 2008 Oct 9. [PubMed:18841445]
  3. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. doi: 10.1152/ajpgi.00102.2009. Epub 2009 Jun 18. [PubMed:19541926]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Methotrexate transporter activity
Specific Function
Has been shown to act both as an intestinal proton-coupled high-affinity folate transporter and as an intestinal heme transporter which mediates heme uptake from the gut lumen into duodenal epithel...
Gene Name
SLC46A1
Uniprot ID
Q96NT5
Uniprot Name
Proton-coupled folate transporter
Molecular Weight
49770.04 Da
References
  1. Nakai Y, Inoue K, Abe N, Hatakeyama M, Ohta KY, Otagiri M, Hayashi Y, Yuasa H: Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther. 2007 Aug;322(2):469-76. Epub 2007 May 2. [PubMed:17475902]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [PubMed:22541068]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [PubMed:22541068]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [PubMed:22541068]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:45